B+
Bull case
20%
Probability
Target price
$22.00
+17.5% vs current
ADPT
Adaptive BiotechnologiesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$18.00
-3.9% vs current
B-
Bear case
20%
Probability
Target price
$8.00
-57.3% vs current
AI sentiment snapshot
Latest data as of 2026-01-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+35.8
Score
AI commentary
Market commentary around the Jan 13 preliminary release has been cautiously constructive — coverage snippets show analyst averages near $18–21, indicating upside vs the anchor for many desks [#SERP-2]. News flow is focused on MRD commercial traction and upcoming final results, creating a mix of optimism and execution caution [#SERP-1].
RankAlpha Sentiment AI - 2026-01-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-02-28eventFinal Q4 & Full Year 2025 Results and Conference CallHigh impact
Company published preliminary results on Jan 13, 2026 and announced it will publish final Q4/FY2025 results and host a conference call; final release + call may materially reprice shares (assumed conference call by 2026-02-28 based on IR notice) [#SERP-1].
2026-04-16catalystAnalyst revisions and updated guidanceHigh impact
Consensus/street targets show a cluster near $18–21; company commentary or results could trigger near-term target revisions and repricing (using a conservative 90-day horizon) [sanity-check: analyst snippets at [#SERP-2], [#SERP-3]].
2027-01-16catalystMRD commercial ramp and reimbursement progressHigh impact
Sustained adoption of MRD assays and favorable reimbursement decisions would drive durable revenue growth and margin expansion; conservative expected date set one year out to reflect multi-quarter commercial build [assumption: +365 days] [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-16 • Updated nightlySource: Internal modelMethodology